Alector, Inc. is a US-based pharmaceutical company specializing in innovative treatments for neurodegenerative diseases. With an ESG risk rating score of 27.3, Alector Inc. is considered a medium-risk investment. The company focuses on developing therapies that target brain pathologies by restoring immune function. Their pipeline includes promising products like AL001, AL002, AL003, and AL101.